Engineering and results of next-generation COVID-19 vaccines.
Leveraging the power of automation for rapid synthesis and discovery of vaccines
With the demonstrated success of mRNA-based vaccines for COVID-19, there has been a growing force of innovative biotechs and biopharma leaders that are leveraging the power of mRNA platforms to advance vaccine development.
As experts look to optimize this relatively nascent platform to advance its applications, one of the key challenges to address is the synthesis of high-quality mRNA for discovery and development. Currently acquiring mRNA for screening vaccine candidates is a widely acknowledged bottleneck in the discovery process.
Telesis Bio’s collaborators at RNAimmune are overcoming this challenge with the BioXp® 3250 automated synthetic biology workstation.
"In our current work identifying mRNA vaccine candidates for infectious diseases, we are always looking for ways to enhance our efficiency. One of the bottlenecks we identified has been the challenge in building or obtaining synthetic constructs for rapid candidate screening. By using BioXp® automated system, we were able to achieve greater speed and throughput in our screening process."
David M. Brown, Ph.D
Associate Director RNAimmune, Inc.
In this talk sponsored by Telesis Bio, Dr. David Brown, Associate Director, R&D at RNAimmune presents an intro into the key technology, tools and knowhow driving their mRNA vaccine development programs. He describes how their team utilized the BioXp® system to develop an automation workflow that helped to rapidly generate vaccine candidates for screening and shorten the time from concept to discovery.
In this short talk Dr. Brown will touch on the following topics:
- Design and synthesis of COVID-19 vaccine
- Broad neutralization across several SARS-CoV-2 strains from preclinical data
- Rapid synthesis and cloning workflow of COVID-19 vaccine variants using the automated BioXp® system
